28.00GBp0.00%Mkt Cap: 42.40M $P/E: —Today
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a T…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap42.40M $
Enterprise Value39.21M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-4.82M $
Revenue/Share—
Last Price28.00 GBp
Fiscal Year EndJun 2025
MR QuarterDec 2025
Employees5
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.08
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B32.10
EPS (TTM)-0.04
EPS (Forward)-3.60
52W Range
9.50090% of range30.00
52W High30.00 GBp
52W Low9.500 GBp
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-194.91%
ROA-104.92%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.77M $
CapEx (TTM)—
FCF Margin—
FCF Yield-2.40%
Net Debt-2.70M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio1.58
Quick Ratio1.58
Book Value/Sh0.0090 GBp
Cash/Share0.0180 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateMar 1, 2022
Analyst Consensus
Rating—
Target (Mean)41.60 GBp
Upside (mean)+48.6%
Target Range41.60 GBp – 41.60 GBp
# Analysts1
Ownership
Shares Out.139.33M
Float132.21M
Insiders6.46%
Institutions0.00%
Technical
SMA 5023.13 (+21.1%)
SMA 20018.84 (+48.6%)
Beta-0.59
S&P 52W Chg18.16%
Avg Vol (30d)230.65K
Avg Vol (10d)337.41K
Technical Indicators
RSI (14)71.4
MACD1.2812
MACD Signal0.6786
MACD Hist.+0.6025
BB Upper28.49 GBp
BB Middle23.85 GBp
BB Lower19.22 GBp
BB Width38.86%
ATR (14)2.083 GBp
Vol Ratio (20d)1.08x